Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Researchers Want Magic Mushrooms Reclassified to Schedule IV

Scientists at Johns Hopkins believe psilocybin should be classified as a schedule IV drug to facilitate its path to the clinic.

Mushrooms / Image: Getty Images
Mushrooms / Image: Getty Images

A recent HUB article discussed the potential reclassification of hallucinogenic mushrooms in the medical world. Currently, psilocybin is a schedule 1 drug, implying it has no medical potential. Researchers working with the drug believe it’s an effective treatment for smoking cessation and disorders like cancer-specific depression and anxiety and therefore believe it should be reclassified as schedule IV. Schedule IV drugs include prescription sleep aids and have a low potential for abuse or dependence.

The scientists are suggesting the reclassification of magic mushrooms in order to facilitate their path to the clinic and minimize logistical hurdles in the future, according to Matthew W. Johnson, associate professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine. Psilocybin must clear phase III clinical trials before the FDA can be petitioned to reclassify it, which could happen in the next five years.

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report